Can Hydroxychloroquine Contain Spread of COVID-19 in Patients?
The anti-malarial drug hydroxychloroquine has shot to fame, owing to its efficacy in shortening the time taken for recovery from COVID-19. Fewer side effects associated with these medicines are encouraging manufacturers in the hydroxychloroquine drugs market to boost their output capacities. Over-the-counter distribution and inexpensive nature of hydroxychloroquine are being preferred by caretakers in home quarantine environments. However, these drugs are under scrutiny for lab-controlled testing, since there is lack of evidence about human trails.
It has been found that hydroxychloroquine alone or in combination with azithromycin can reduce virus levels quicker. Such findings have prompted drug regulators in several countries, including India to approve the drug in restricted settings. Hydroxychloroquine is found to trigger a hyperactive response by the immune system, which helps to minimize the symptoms. These factors are likely to drive the hydroxychloroquine drugs market during the forecast period.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111833
High Prevalence of Childhood Arthritis Cases and Autoimmune Diseases Triggers Market Growth
The hydroxychloroquine drugs market is predicted to clock a robust CAGR of 10% during the forecast period. Hydroxychloroquine (Plaquenil) is considered as a disease-modifying anti-rheumatic drug. The high prevalence of joint pain and long-term disability in individuals has catalyzed the demand for hydroxychloroquine drugs. Plaquenil is being highly publicized for effectively reducing pain and swelling of arthritis.
An alarmingly high number of childhood arthritis cases and other autoimmune diseases are acting as key drivers for the hydroxychloroquine drugs market. However, the drug may lead to severe hypoglycemia. Thus, diabetic patients are advised to regularly monitor their blood sugar levels. On the other hand, it has been found that hydroxychloroquine is not effective against malaria in areas where chloroquine resistance has been reported. Hence, pharma companies are advocating a better understanding of poor quality drugs on malaria control.
Pooled Analysis of Hydroxychloroquine Provides Drug Resistance Status
Hydroxychloroquine drugs are the gold standard for the treatment of malaria. However, in many cases, healthcare professionals have encountered drug resistance in patients, which is likely to affect the growth of the hydroxychloroquine drugs market. Poorly administered medicines and substandard treatments are affecting the sales of hydroxychloroquine drugs. Hence, manufacturers in the hydroxychloroquine drugs market are taking ques from the WorldWide Antimalarial Resistance Network (WWARN), which is facilitating study groups that generate a pooled analysis of the efficacy and safety of hydroxychloroquine drugs.
Freely available training courses, tools and resources are being employed to provide regional researchers with the knowledge and skills to generate high-quality antimalarial clinical data. As such, the FDA (Food and Drug Administration) approval for hydroxychloroquine is being highly preferred for rheumatoid arthritis and systemic lupus erythematosis treatment.
Decreased Disease Flares to Offset Disadvantages of Toxicity
The global hydroxychloroquine drugs market is expected to cross US$ 1.9 Bn by 2030, as manufacturers are increasing their output capacities that cater to the treatment of systemic lupus erythematosus. Research into the wide-ranging effects of hydroxychloroquine reveals that several benefits involving decrease in disease flares and decline in the number of antigen-presenting cells in the skin are bolstering market growth.
The decline in the damage from disease over time and the hydroxychloroquine’s ability to delay absorption of ultraviolet light (UV) are helping pharma companies boost their production capacities. However, patients with retinal dystrophy or macular degeneration are susceptible to toxicity due to hydroxychloroquine administration. Hence, companies in the hydroxychloroquine drugs market are encouraging patients to conduct annual examinations with qualified retina specialists to control toxicity levels.
Companies in the hydroxychloroquine drugs market have increased their output capacities during the COVID-19 pandemic. However, the FDA has issued a caution against hydroxychloroquine outside of hospital settings due to the potential risk of heart rhythm problems. Juvenile idiopathic arthritis and high prevalence of lupus in individuals are boosting the growth of the hydroxychloroquine drugs market. However, issues of drug resistance are being encountered by several healthcare professionals. Hence, pharma companies are designing data visualization and mapping tools to track the spread of drug resistance. Such data is being handed over to government-led surveillance agencies to introduce high-quality drugs in the market.
View full report@ https://qyresearchmedical.com/report/hydroxychloroquine-drugs-market-disease-indication-malaria-rheumatoid-arthritis-covid-19-systemic-lupus-erythematosus-and-others-and-distribution-channel-hospital-pharmacies-retail-pharmacies-and-online-ph-2020-2030/111833
Hydroxychloroquine Drugs Market: Overview
Hydroxychloroquine (HCQ) belongs to a class of drugs called antimalarials. It is used to treat rheumatoid arthritis and systemic lupus erythematosus by decreasing the activity of the immune system. In 2020, hydroxychloroquine gained popularity as a treatment for coronavirus (COVID-19). However, HCQ tablets are currently under clinical trial as a possible treatment for COVID-19 and their efficacy in treating COVID-19 is yet to be demonstrated in the studies.
Rise in prevalence of malaria and rheumatoid arthritis, and increase in geriatric population are projected to drive the global hydroxychloroquine drugs market. Surge in product launches and approvals are anticipated to augment the global market in the near future.
Hydroxychloroquine Drugs Market: Key Drivers
Hydroxychloroquine is FDA-approved to treat or prevent malaria. Hydroxychloroquine is also approved for treatment of autoimmune conditions such as chronic discoid lupus erythematosus, systemic lupus erythematosus in adults, and rheumatoid arthritis. According to CDC, nearly half the world’s population lives in areas at risk of malaria transmission in 91 countries and territories. In 2016, malaria caused an estimated 216 million clinical episodes and 445,000 deaths, which increased to an estimated 228 million cases and 405,000 deaths in 2018. Majority of deaths occurred in the WHO African Region.
Disease outbreaks such as coronavirus also boost the demand for the drug. According the WHO, as on November 23, 2020, 58,425,681 confirmed cases of COVID-19, including 1,385,218 deaths, were reported globally.
Older people are at high risk of rheumatoid arthritis. Depending on their underlying health, older adults with rheumatoid arthritis could have to cope with multiple coexisting diseases, polypharmacy, and impaired functional ability. According the CDC, from 2013 to 2015, 49.6% of people aged 65 years or older in the U.S. reported doctor-diagnosed arthritis.
Increase in Product Launches and Approvals
Product launch strategies aim to boost revenue. More than 25% of total revenue and profits across industries comes from the launch of new products. In April 2020, Lincoln Pharmaceuticals received the FDA approval to manufacture hydroxychloroquine (HCQ) tablets and hydroxychloroquine sulfate tablets. After necessary approval from the Directorate General of Foreign Trade (DGFT), the company will be able to export these products. Rise in number of product approvals is expected to propel the global market during the forecast period.
Market Segmentation: Hydroxychloroquine Drugs Market
In terms of disease indication, the global hydroxychloroquine drugs market has been classified into malaria, rheumatoid arthritis, COVID-19, systemic lupus erythematosus, and others
Based on distribution channel, the global hydroxychloroquine drugs market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies
Each of the segments has been analyzed in detail for trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The hydroxychloroquine drugs market report provides current and future revenue (US$ Mn) for each of these segments for the period from 2018 to 2030, considering 2019 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2020 to 2030, along with market size estimations.
Regional Overview: Hydroxychloroquine Drugs Market
In terms of region, the global hydroxychloroquine drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
Stringent government regulations, presence of large-scale research units, and awareness about drug safety are the key factors projected to augment the market in North America. The market in Asia Pacific is driven by favorable business environment and government initiatives to improve healthcare infrastructure. Moreover, increase in focus on research & development is anticipated to augment the market in the region.
The current and future market sizes in terms of value (US$ Mn) of these regional markets and major countries have been provided in the report for the period from 2018 to 2030, along with their CAGRs for the period from 2020 to 2030
The study also offers a list of recommendations, highlights, and useful insights of the market, which are estimated to help new companies willing to enter the market and existing companies to increase market share and in the decision-making process
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111833/2900
The report concludes with company profiles section that includes key information about the major players in the global hydroxychloroquine drugs market
Leading players analyzed in the report are
- Amneal Pharmaceuticals, Inc.
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Zydus Cadila
- Dr. Reddy’s Laboratories Ltd.
- Sun Pharmaceutical Industries Ltd.
- Lupin Limited
- Prasco Laboratories
Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments
Key Questions Answered in Hydroxychloroquine Drugs Report
- What is the sales/revenue generated by hydroxychloroquine drug providers across all regions during the forecast period?
- What are the opportunities in the global hydroxychloroquine drugs market?
- What are the major drivers, restraints, and threats in the global market?
- Which region is set to expand at the fastest CAGR during the forecast period?
- Which distribution channel segment is expected to generate the highest revenue globally in 2030? Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?
Hydroxychloroquine Drugs Market – Segmentation
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
TABLE OF CONTENT
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Hydroxychloroquine Drugs Market
4. Market Overview
4.1. Introduction & Overview
4.2. Market Dynamics
4.3. Global Hydroxychloroquine Drugs Market Analysis and Forecast, 2018–2030
5. Market Outlook
5.1. COVID-19 Pandemics Impact on Industry
5.2. Regulatory Scenario by Region/globally
5.3. Disease Prevalence & Incidence Rate globally with key countries
6. Global Hydroxychloroquine Drugs Market Analysis and Forecast, by Disease Indication
6.1. Introduction & Definition
6.2. Global Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2018–2030
6.2.2. Rheumatoid Arthritis
6.2.4. Systemic Lupus Erythematosus
6.3. Global Hydroxychloroquine Drugs Market Attractiveness Analysis, by Disease Indication
7. Global Hydroxychloroquine Drugs Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Global Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
7.2.1. Hospital Pharmacies
7.2.2. Retail Pharmacies
7.2.3. Online Pharmacies
7.3. Global Hydroxychloroquine Drugs Market Attractiveness Analysis, by Distribution Channel
8. Global Hydroxychloroquine Drugs Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Global Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Region
8.2.1. North America
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Hydroxychloroquine Drugs Market Attractiveness Analysis, by Region
9. North America Hydroxychloroquine Drugs Market Analysis and Forecast
9.2. North America Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2018–2030
9.2.2. Rheumatoid Arthritis
9.2.4. Systemic Lupus Erythematosus
9.3. North America Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. North America Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Country, 2018–2030
9.5. North America Hydroxychloroquine Drugs Market Attractiveness Analysis
9.5.1. By Disease Indication
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Hydroxychloroquine Drugs Market Analysis and Forecast
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111833/2900
You can place an order or ask any questions, please feel free to contact firstname.lastname@example.org | +1 9197 992 333
QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.
For Latest Update Follow Us: